PetIQ, Inc. Reports Record First Quarter 2022 Financial Results
Reports First Quarter Net Sales of $275.7 Million
Company Provides Second Quarter 2022 Guidance and Reiterates Full Year 2022 Outlook
EAGLE, Idaho, May 04, 2022 (GLOBE NEWSWIRE) -- PetIQ, Inc. (“PetIQ” or the “Company”) (Nasdaq: PETQ), a leading pet medication and wellness company, today reported financial results for the first quarter ended March 31, 2022.
Cord Christensen, PetIQ’s Chairman & CEO commented, “We started 2022 off strong. Our first quarter financial results exceeded our guidance driven by both our Products and Services segments. We benefitted from higher-than-normal fill rates at our retail and e-commerce partners in preparation for the flea and tick season, new product innovation and our ability to have more mobile community clinics in operation than we projected in the quarter. As a result, we are reiterating our annual outlook for 2022 and believe we are well positioned to drive net sales growth, profitability, and increase our cash flow generation. Moving forward, our team continues to execute on our mission of delivering smarter options for pet parents to help enrich their pet's lives through convenient and affordable access to veterinarian products and services.”
First Quarter 2022 Highlights Compared to Prior Year Period
- Record net sales of $275.7 million compared to $254.3 million, an increase of 8.4%; for comparative purposes, net sales increased 17.8%, excluding $20.2 million of sales related to loss of distribution rights for certain animal health manufacturing products, previously communicated
- Product segment net sales of $247.8 million compared to $230.0 million, an increase of 7.7%; Product segment net sales increased 18.1% excluding the aforementioned item
- PetIQ’s manufactured products increased to 26.6% of Product segment net sales compared to 22.4%
- Services segment net revenues of $27.9 million compared to $24.3 million, an increase of 14.9%
- Gross margin increased 210 basis points to 20.9%; adjusted gross margin increased 270 basis points to 23.6%
- Net income increased 32.4% to $3.2 million, or earnings per diluted share of $0.11, compared to $2.4 million, or earnings per diluted share of $0.08
- Adjusted net income increased 66.0% to $18.3 million, or earnings per diluted share of $0.62, compared to $11.0 million, or earnings per diluted share of $0.41, an increase of 51.2%
- Adjusted EBITDA of $31.6 million compared to $26.9 million, an increase of 17.6%
- Adjusted EBITDA margin increased 90 basis points to 11.5%
- Four new wellness center openings in the first quarter of 2022
First Quarter 2022 Financial Results
Record net sales of $275.7 million for the first quarter of 2022, increased 8.4%, compared to $254.3 million for the same period in the prior year. For comparative purposes, net sales increased 17.8%, excluding $20.2 million of sales related to loss of distribution rights for certain animal health manufacturing products, previously communicated. First quarter net sales were driven by growth in both the Product and Services segments. The Product segment benefited from broad-based growth across categories and sales channels with continued strength in manufactured products and new product innovation as well as stronger than normal fill orders for the start of the flea and tick season that resulted in a shift of timing of $5.0 million of sales to the first quarter of 2022 which were expected to occur in the second quarter of 2022. The increase in Services segment net revenues was driven by improved revenue metrics at the wellness centers as compared to the prior year period and optimization of the mobile clinics. Product segment net sales were $247.8 million and Services segment net revenues were $27.9 million in the first quarter of 2022.
First quarter 2022 gross profit was $57.6 million, an increase of 20.6% compared to $47.8 million in the prior year period. Gross margin increased 210 basis points to 20.9% from 18.8% in the prior year period. Adjusted gross profit was $63.3 million, an increase of 21.0% compared to $52.3 million in the prior year period, reflecting favorable product mix including the growth in sales of the Company’s manufactured product portfolio including launched products such as NextStar and reflects the benefit of Services segment optimization. Adjusted gross margin increased 270 basis points to 23.6% for the first quarter 2022 compared to 20.9% in the prior year period.
Selling, general and administrative expenses (“SG&A”) was $48.2 million for the first quarter of 2022 compared to $40.7 million in the prior year period. Adjusted SG&A was $38.9 million for the first quarter of 2022 compared to $36.7 million in the prior year period. As a percentage of net sales adjusted SG&A was 14.5% a decrease of 20 basis points compared to the prior year period. The Company achieved leverage on its SG&A expenses as a percent of net sales despite an incremental $2.8 million, or 100 basis points of expense, to support two of the Company’s significant new manufactured brand introductions and continued marketing investments to help accelerate growth of its manufactured brand product portfolio.
Net income was $3.2 million for the first quarter of 2022, an increase of 32.4%, compared to $2.4 million in the prior year period. The Company reported earnings per diluted share of $0.11 compared to $0.08 in the first quarter of 2021. Adjusted net income was $18.3 million, an increase of 66.0%, compared to $11.0 million in the prior year period. The Company reported adjusted earnings per diluted share of $0.62 compared to $0.41 in the first quarter of 2021.
First quarter adjusted EBITDA was $31.6 million, an increase of 17.6%, compared to $26.9 million in the prior year period. Adjusted EBITDA margin increased 90 basis points to 11.5% compared to 10.6% in the prior year period which reflects the operating leverage generated in the quarter as a result of stronger margin on higher sales and the incremental profit.
Adjusted gross profit, adjusted gross margin, adjusted SG&A, adjusted net income, Non-GAAP adjusted EPS, adjusted EBITDA, and adjusted EBITDA margin are non-GAAP financial measures. The Company believes these non-GAAP financial measures provide investors with additional insight into the way management views reportable segment operations. See “Non-GAAP Financial Measures” for a definition of these measures and the financial tables that accompany this release for a reconciliation to the most comparable GAAP measure.
Segment Results
Product:
For the first quarter of 2022, Product segment net sales increased 7.7% to $247.8 million from $230.0 million in the prior year period. For comparative purposes, Product segment net sales increased 18.1%, excluding $20.2 million in sales related to loss of distribution rights for certain animal health manufacturing products, as previously communicated the last few quarters. A reconciliation table of reported net sales to pro forma net sales and adjusted EBITDA for the first quarter of 2022 and 2021 are included in this release. The Product segment benefited from broad-based growth across categories and sales channels with continued strength in manufactured products and new product innovation as well as stronger than normal fill orders for the start of the flea and tick season that resulted in a shift of timing of $5.0 million of sales to the first quarter of 2022 from the second quarter of 2022.
Product segment adjusted EBITDA increased 23.5% to $47.9 million from adjusted EBITDA of $38.8 million in the first quarter of 2021. Product segment adjusted EBITDA margin in the first quarter of 2022 increased 250 basis points to 19.3% compared to the prior year period.
Services:
For the first quarter of 2022, Services segment net revenues were $27.9 million, an increase of 14.9% compared to $24.3 million in the same period last year. The increase in Services segment net revenues was driven by improved revenue metrics at the wellness centers as compared to the prior year period and optimization of the mobile clinics. Services segment adjusted EBITDA was $3.1 million an increase of 47.1% compared to $2.1 million in the first quarter of 2021.
Cash Flow and Balance Sheet
As of March 31, 2022, the Company had cash and cash equivalents of $51.1 million. The Company’s long-term debt, which is comprised of its term loan, ABL, and convertible debt, was $472.9 million as of March 31, 2022. The Company had total liquidity, which it defines as cash on hand plus availability, of $151.1 million as of March 31, 2022.
Outlook
The Company is reiterating its annual outlook and providing second quarter 2022 guidance.
For the full year 2022 the Company expects:
- Net sales of approximately $985 million representing an increase of 5.6% compared to 2021. For comparative purposes, the Company expects net sales to increase approximately 10.0% excluding $36.1 million of sales related to loss of distribution rights for certain animal health manufacturing products, previously communicated the last few quarters.
- Adjusted EBITDA of approximately $100 million representing an increase of 7.6% compared to 2021. For comparative purposes, the Company expects adjusted EBITDA to increase approximately 10.0%, excluding $1.8 million in adjusted EBITDA related to loss of distribution rights for certain animal health manufacturing products, previously communicated the last few quarters.
The Company’s annual adjusted EBITDA outlook continues to assume adjusted SG&A will increase approximately 100 basis points to 17.3% in 2022 compared to 16.3% in 2021 as a result of an incremental $15 million, or 150 basis points of marketing investments, to support its launch into direct-to-consumer channels, two significant new manufactured brand introductions, and to help accelerate growth of its manufactured brand product portfolio. Approximately $2.8 million of the aforementioned SG&A expense was incurred in the first quarter of 2022, $7.0 million expected in the second quarter of 2022 with the balance expected to be incurred in the third quarter of 2022. The annual outlook also assumes nominal improvement in adjusted EBITDA contribution from the Services segment given the continued volatility in the segment’s results as a result of the ongoing impact to the veterinarian labor market from the global pandemic.
The Company is updating its expectations for 2022 net sales seasonality. As a result of a shift in timing of $5.0 million in orders and sales to the first quarter of 2022 from the second quarter of 2022, and a slower start than normal in the month of April of the flea and tick season causing the Company’s customers to currently have inflated inventory levels in the second quarter, it now expects the second quarter of 2022 pro forma net sales to be consistent with the second quarter of 2021. Beginning the last week of April, the Company has experienced a more normalized trend to its seasonal flea and tick sales and the Company’s second quarter guidance assumes this trend will continue. For the first half of 2022 the Company expects pro forma net sales to increase approximately 9.0% compared to the first half of 2021. PetIQ continues to expect most of the net sales growth in the second half of 2022 will be weighted to the third quarter.
For the second quarter of 2022 the Company expects:
- Net sales of approximately $260 million compared to $271 million of net sales in the second quarter of 2021. For comparative purposes, the Company expects net sales to be flat to second quarter of 2021 when excluding $11.8 million of sales related to loss of distribution rights for certain animal health manufacturing products, previously communicated the last few quarters. As noted above there is also a shift in timing of $5.0 million in orders and sales to the first quarter of 2022 from the second quarter of 2022, and the noted slower start than normal in the month of April of the flea and tick season.
- Adjusted EBITDA of approximately $28 million compared to $34.8 million in the second quarter of 2021. The Company’s second quarter of 2022 adjusted EBITDA outlook assumes adjusted SG&A as a percent of net sales to be 340 basis points higher than the second quarter of 2021 at 17.5%, due to an incremental $7.0 million, or approximately 260 basis points of expense, to support two of its significant new manufactured brand introductions and continued marketing investments to help accelerate growth of its manufactured brand product portfolio.
Announces Executive Leadership Team Changes
In a separate press release today, the Company announced that Susan Sholtis will leave the Company as President on May 27, 2022, to spend more time with her family. Michael Smith, who has served as the Company’s Executive Vice President, Products Division since 2019, has been appointed President and Chief Operating Officer, a newly created role, effective June 1, 2022. Smith will continue to report directly to Cord Christensen, Chief Executive Officer. Sholtis will remain available on an as needed basis to ensure a smooth transition through September 30, 2022.
Conference Call and Webcast
The Company will host a conference call with members of the executive management team to discuss these results with additional comments and details. The conference call is scheduled to begin today at 4:30 p.m. ET. To participate on the live call listeners in North America may dial 877-451-6152 and international listeners may dial 201-389-0879.
In addition, the call will be broadcast live over the Internet hosted at the “Investors” section of the Company's website at www.PetIQ.com. A telephonic playback will be available through May 25, 2022. North American listeners may dial 844-512-2921 and international listeners may dial 412-317-6671; the passcode is 13729092.
About PetIQ
PetIQ is a leading pet medication and wellness company delivering a smarter way for pet parents to help their pets live their best lives through convenient access to affordable veterinary products and services. The company engages with customers through more than 60,000 points of distribution across retail and e-commerce channels with its branded and distributed medications, which is further supported by its own world-class medications manufacturing facility in Omaha, Nebraska. The company’s national service platform, VIP Petcare, operates in over 2,900 retail partner locations in 42 states providing cost effective and convenient veterinary wellness services. PetIQ believes that pets are an important part of the family and deserve the best products and care we can give them.
Contact: [email protected] or 208.513.1513
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, such as statements about our plans, objectives, expectations, assumptions or future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “estimate,” “plan,” “project,” “continuing,” “ongoing,” “expect,” “believe,” “intend,” “may,” “will,” “should,” “could” and similar expressions. Forward-looking statements involve estimates, assumptions, known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from any future results, performances, or achievements expressed or implied by the forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time those statements are made or management's good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause such differences include, but are not limited to, the impact of COVID-19 on our business and the global economy; our ability to successfully grow our business through acquisitions; our dependency on a limited number of customers; our ability to implement our growth strategy effectively; competition from veterinarians and others in our industry; reputational damage to our brands; economic trends and spending on pets; the effectiveness of our marketing and trade promotion programs; recalls or withdrawals of our products or product liability claims; our ability to manage our manufacturing and supply chain effectively; disruptions in our manufacturing and distribution chains; our ability to introduce new products and improve existing products; our ability to protect our intellectual property; costs associated with governmental regulation; our ability to keep and retain key employees; our ability to sustain profitability; and the risks set forth under the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2021 and other reports filed time to time with the Securities and Exchange Commission.
Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or operating results. The forward-looking statements speak only as of the date on which they are made, and, except as required by law, we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Consequently, you should not place undue reliance on forward-looking statements.
Non-GAAP Financial Measures
In addition to financial results reported in accordance with U.S. GAAP, PetIQ uses the following non-GAAP financial measures: Adjusted net income, non-GAAP adjusted earnings per share, adjusted gross profit, adjusted gross margin, adjusted SG&A, adjusted EBITDA, and adjusted EBITDA margin.
Adjusted net income consists of net income adjusted for tax expense, acquisition expenses, integration costs and costs of discontinued clinics, non-same-store revenue, non-same-store costs, litigation costs, stock-based compensation expense, and COVID-19 related costs. Adjusted net income is utilized by management to evaluate the effectiveness of our business strategies. Non-GAAP adjusted earnings per share is defined as non-GAAP adjusted net income divided by the weighted average number of shares of common stock outstanding during the period.
Adjusted gross profit consists of gross profit adjusted for gross (profit) loss on veterinarian clinics and wellness centers that are not part of same store sales. Adjusted gross profit is utilized by management to evaluate the effectiveness of our business strategies.
Adjusted SG&A consists of SG&A adjusted for acquisition expenses, stock-based compensation expense, non-same store adjustment, integration costs and costs of discontinued clinics, and litigation expense.
EBITDA, Adjusted EBITDA and Adjusted EBITDA margin are non-GAAP financial measures. EBITDA represents net income before interest, income taxes and depreciation and amortization. Adjusted EBITDA represents EBITDA plus adjustments for transactions that management does not believe are representative of our core ongoing business. Adjusted EBITDA margin is adjusted EBITDA stated as a percentage of net sales. Adjusted EBITDA is utilized by management: (i) as a factor in evaluating management's performance when determining incentive compensation, (ii) to evaluate the effectiveness of our business strategies and (iii) allow for improved comparability over prior periods due to significant growth in the Company’s new wellness centers. The Company presents EBITDA because it is a necessary component for computing adjusted EBITDA.
We believe that the use of adjusted net income, Non-GAAP adjusted EPS, adjusted gross profit, adjusted gross margin, adjusted selling, general and administrative expenses (Adjusted SG&A), adjusted EBITDA, and adjusted EBITDA margin provide additional tools for investors to use in evaluating ongoing operating results and trends. In addition, you should be aware when evaluating adjusted net income, adjusted gross profit, adjusted SG&A, adjusted EBITDA (and accordingly, non-GAAP adjusted earnings per share and adjusted EBITDA margin), that in the future we may incur expenses similar to those excluded when calculating these measures. Our presentation of these measures should not be construed as an inference that our future results will be unaffected by these or other unusual or non-recurring items. Our computation of adjusted net income, adjusted gross profit, adjusted gross margin, adjusted SG&A, adjusted EBITDA and adjusted EBITDA margin may not be comparable to other similarly titled measures computed by other companies, because all companies do not calculate adjusted net income, adjusted gross profit, adjusted SG&A, adjusted EBITDA and adjusted EBITDA margin in the same manner. Our management does not, and you should not, consider adjusted net income, adjusted gross profit, adjusted gross margin, adjusted SG&A, adjusted EBITDA margin, or adjusted EBITDA in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of adjusted net income, adjusted gross profit, adjusted gross margin, adjusted SG&A, adjusted EBITDA margin, and adjusted EBITDA is that they exclude significant expenses and income that are required by GAAP to be recorded in our financial statements. See a reconciliation of non-GAAP measures to the most comparable GAAP measure, in the financial tables that accompany this release.
Definitions
- Mobile clinic – A mobile clinic is defined as an event, or a visit to a retail host partner location, by the Company’s veterinary staff utilizing the Company’s mobile service vehicles. Clinic locations and schedules vary by location and seasonally. Due to the non-standardization of the Company’s mobile clinics, these clinics are grouped as part of geographic regions.
- Wellness center – A wellness center is a physical fixed service location within the existing footprint of one of our retail partners. These wellness centers operate under a variety of brands based on the needs of our partner locations.
PetIQ, Inc.
Condensed Consolidated Balance Sheets(Unaudited, in 000’s except for per share amounts)
| March 31, 2022 | December 31, 2021 | |||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 51,104 | $ | 79,406 | ||||
| Accounts receivable, net | 179,058 | 113,947 | ||||||
| Inventories | 167,714 | 96,440 | ||||||
| Other current assets | 10,148 | 8,896 | ||||||
| Total current assets | 408,024 | 298,689 | ||||||
| Property, plant and equipment, net | 78,194 | 76,613 | ||||||
| Operating lease right of use assets | 19,162 | 20,489 | ||||||
| Other non-current assets | 1,970 | 2,024 | ||||||
| Intangible assets, net | 186,111 | 190,662 | ||||||
| Goodwill | 230,973 | 231,110 | ||||||
| Total assets | $ | 924,434 | $ | 819,587 | ||||
| Liabilities and equity | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 128,913 | $ | 55,057 | ||||
| Accrued wages payable | 11,236 | 12,704 | ||||||
| Accrued interest payable | 5,099 | 3,811 | ||||||
| Other accrued expenses | 13,709 | 11,680 | ||||||
| Current portion of operating leases | 6,047 | 6,500 | ||||||
| Current portion of long-term debt and finance leases | 8,411 | 8,350 | ||||||
| Total current liabilities | 173,415 | 98,102 | ||||||
| Operating leases, less current installments | 14,300 | 14,843 | ||||||
| Long-term debt, less current installments | 472,945 | 448,470 | ||||||
| Finance leases, less current installments | 2,164 | 2,493 | ||||||
| Other non-current liabilities | 451 | 459 | ||||||
| Total non-current liabilities | 489,860 | 466,265 | ||||||
| Equity | ||||||||
| Additional paid-in capital | 371,398 | 368,006 | ||||||
| Class A common stock, par value $0.001 per share, 125,000 shares authorized; 29,272 and 29,139 shares issued and outstanding, respectively | 29 | 29 | ||||||
| Class B common stock, par value $0.001 per share, 100,000 shares authorized; 252 and 272 shares issued and outstanding, respectively | — | — | ||||||
| Accumulated deficit | (111,394 | ) | (114,525 | ) | ||||
| Accumulated other comprehensive loss | (1,136 | ) | (684 | ) | ||||
| Total stockholders' equity | 258,897 | 252,826 | ||||||
| Non-controlling interest | 2,262 | 2,394 | ||||||
| Total equity | 261,159 | 255,220 | ||||||
| Total liabilities and equity | $ | 924,434 | $ | 819,587 | ||||
PetIQ, Inc.
Condensed Consolidated Statements of Operations (Unaudited, in 000’s, except for per share amounts)
| For the Three Months Ended | ||||||||
| March 31, 2022 | March 31, 2021 | |||||||
| Product sales | $ | 247,750 | $ | 230,034 | ||||
| Services revenue | 27,945 | 24,313 | ||||||
| Total net sales | 275,695 | 254,347 | ||||||
| Cost of products sold | 190,851 | 182,827 | ||||||
| Cost of services | 27,209 | 23,721 | ||||||
| Total cost of sales | 218,060 | 206,548 | ||||||
| Gross profit | 57,635 | 47,799 | ||||||
| Operating expenses | ||||||||
| Selling, general and administrative expenses | 48,236 | 40,672 | ||||||
| Operating income | 9,399 | 7,127 | ||||||
| Interest expense, net | 6,121 | 4,870 | ||||||
| Other income, net | (3 | ) | (204 | ) | ||||
| Total other expense, net | 6,118 | 4,666 | ||||||
| Pretax net income | 3,281 | 2,461 | ||||||
| Income tax expense | (121 | ) | (75 | ) | ||||
| Net income | 3,160 | 2,386 | ||||||
| Net income attributable to non-controlling interest | 29 | 353 | ||||||
| Net income attributable to PetIQ, Inc. | $ | 3,131 | $ | 2,033 | ||||
| Net income per share attributable to PetIQ, Inc. Class A common stock | ||||||||
| Basic | $ | 0.11 | $ | 0.08 | ||||
| Diluted | $ | 0.11 | $ | 0.08 | ||||
| Weighted Average shares of Class A common stock outstanding | ||||||||
| Basic | 29,164 | 26,386 | ||||||
| Diluted | 29,290 | 27,004 | ||||||
PetIQ, Inc.Condensed Consolidated Statements of Cash Flows(Unaudited, in 000’s)
| For the Three Months Ended March 31, | ||||||||
| 2022 | 2021 | |||||||
| Cash flows from operating activities | ||||||||
| Net income | $ | 3,160 | $ | 2,386 | ||||
| Adjustments to reconcile net income to net cash used in operating activities | ||||||||
| Depreciation, amortization of intangible assets and loan fees | 8,966 | 12,351 | ||||||
| Loss on disposition of property, plant, and equipment | 148 | 30 | ||||||
| Stock based compensation expense | 3,823 | 2,122 | ||||||
| Other non-cash activity | 316 | 145 | ||||||
| Changes in assets and liabilities | ||||||||
| Accounts receivable | (65,026 | ) | (72,423 | ) | ||||
| Inventories | (71,417 | ) | (32,767 | ) | ||||
| Other assets | (1,273 | ) | (726 | ) | ||||
| Accounts payable | 74,094 | 32,182 | ||||||
| Accrued wages payable | (1,496 | ) | (2,184 | ) | ||||
| Other accrued expenses | 3,325 | 1,531 | ||||||
| Net cash used in operating activities | (45,380 | ) | (57,353 | ) | ||||
| Cash flows from investing activities | ||||||||
| Purchase of property, plant, and equipment | (5,678 | ) | (8,325 | ) | ||||
| Net cash used in investing activities | (5,678 | ) | (8,325 | ) | ||||
| Cash flows from financing activities | ||||||||
| Proceeds from issuance of long-term debt | 40,000 | 242,500 | ||||||
| Principal payments on long-term debt | (16,150 | ) | (204,641 | ) | ||||
| Principal payments on finance lease obligations | (399 | ) | (468 | ) | ||||
| Tax withholding payments on Restricted Stock Units | (688 | ) | (802 | ) | ||||
| Exercise of options to purchase class A common stock | 100 | 6,580 | ||||||
| Net cash provided by financing activities | 22,863 | 43,169 | ||||||
| Net change in cash and cash equivalents | (28,195 | ) | (22,509 | ) | ||||
| Effect of exchange rate changes on cash and cash equivalents | (107 | ) | 117 | |||||
| Cash and cash equivalents, beginning of period | 79,406 | 33,456 | ||||||
| Cash and cash equivalents, end of period | $ | 51,104 | $ | 11,064 | ||||
PetIQ, Inc.Summary Segment Results(Unaudited, in 000’s)
| For the three months ended | ||||||||
| $'s in 000's | March 31, 2022 | March 31, 2021 | ||||||
| Products segment sales | $ | 247,750 | $ | 230,034 | ||||
| Services segment revenue: | ||||||||
| Same-store sales | 20,725 | 19,918 | ||||||
| Non same-store sales | 7,220 | 4,395 | ||||||
| Total services segment revenue | 27,945 | 24,313 | ||||||
| Total net sales | 275,695 | 254,347 | ||||||
| Adjusted EBITDA | ||||||||
| Products | 47,909 | 38,792 | ||||||
| Services | 3,084 | 2,096 | ||||||
| Unallocated Corporate | (19,398 | ) | (14,027 | ) | ||||
| Total Adjusted EBITDA | $ | 31,595 | $ | 26,861 | ||||
PetIQ, Inc.Reconciliation between gross profit and adjusted gross profit(Unaudited, in 000’s)
| For the three months ended | ||||||||
| March 31, 2022 | March 31, 2021 | |||||||
| Gross profit | $ | 57,635 | $ | 47,799 | ||||
| Plus: | ||||||||
| Non same-store gross (profit) loss(2) | 5,709 | 4,539 | ||||||
| Adjusted gross profit | $ | 63,344 | $ | 52,338 | ||||
| Gross Margin % | 20.9 | % | 18.8 | % | ||||
| Adjusted gross margin % | 23.6 | % | 20.9 | % | ||||
PetIQ, Inc.Reconciliation between Selling, General &Administrative (“SG&A”) and Adjusted SG&A(Unaudited, in 000’s)
| For the three months ended | ||||||||
| March 31, 2022 | March 31, 2021 | |||||||
| SG&A | $ | 48,236 | $ | 40,672 | ||||
| Less: | ||||||||
| Acquisition costs(1) | — | 6 | ||||||
| Stock based compensation expense | 3,823 | 2,122 | ||||||
| Non same-store adjustment(2) | 2,465 | 1,685 | ||||||
| Integration costs and costs of discontinued clinics(3) | 339 | (48 | ) | |||||
| Litigation expenses | 2,661 | 243 | ||||||
| Adjusted SG&A | $ | 38,948 | $ | 36,664 | ||||
| % of Sales (GAAP) | 17.5 | % | 16.0 | % | ||||
| % of Sales (Adjusted) | 14.5 | % | 14.7 | % | ||||
PetIQ, Inc.Reconciliation between Net Income and Adjusted EBITDA(Unaudited, in 000’s)
| For the three months ended | ||||||||
| March 31, 2022 | March 31, 2021 | |||||||
| Net income | $ | 3,160 | $ | 2,386 | ||||
| Plus: | ||||||||
| Tax expense | 121 | 75 | ||||||
| Depreciation | 3,682 | 3,131 | ||||||
| Amortization | 4,523 | 8,428 | ||||||
| Interest | 6,121 | 4,870 | ||||||
| EBITDA | $ | 17,607 | $ | 18,890 | ||||
| Acquisition costs(1) | — | 6 | ||||||
| Stock based compensation expense | 3,823 | 2,122 | ||||||
| Non same-store adjustment(2) | 7,165 | 5,648 | ||||||
| Integration costs and costs of discontinued clinics(3) | 339 | (48 | ) | |||||
| Litigation expenses | 2,661 | 243 | ||||||
| Adjusted EBITDA | $ | 31,595 | $ | 26,861 | ||||
| Adjusted EBITDA Margin | 11.5 | % | 10.6 | % | ||||
(1) Acquisition costs include legal, accounting, banking, consulting, diligence, and other costs related to completed and contemplated acquisitions.
(2) Non same-store adjustment includes revenue and costs, and associated gross profit, related to our Services segment wellness centers and host partners with less than six full quarters of operating results, and also include pre-opening expenses.
(3) Integration costs and costs of discontinued clinics represent costs related to integrating the acquired businesses including personnel costs such as severance and signing bonuses, consulting costs, contract termination, and IT conversion costs. Depending on the type of costs, the costs are primarily in the Products segment and the corporate segment. Costs of discontinued clinics represent costs to close Service segment locations.
PetIQ, Inc.Reconciliation between Net Income and Adjusted Net Income(Unaudited, in 000’s, except for per share amounts)
| Three Months Ended | |||||||
| March 31, 2022 | March 31, 2021 | ||||||
| Net income | $ | 3,160 | $ | 2,386 | |||
| Plus: | |||||||
| Tax expense | 121 | 75 | |||||
| Acquisition costs(1) | — | 6 | |||||
| Stock based compensation expense | 3,823 | 2,122 | |||||
| Non same-store adjustment(2) | 8,174 | 6,224 | |||||
| Integration costs and costs of discontinued clinics(3) | 339 | (48 | ) | ||||
| Litigation expenses | 2,661 | 243 | |||||
| Adjusted Net income | $ | 18,278 | $ | 11,009 | |||
| Non-GAAP adjusted EPS | |||||||
| Basic | $ | 0.63 | $ | 0.42 | |||
| Diluted | $ | 0.62 | $ | 0.41 | |||
| Weighted Average shares of Class A common stock outstanding used to compute non-GAAP adjusted EPS | |||||||
| Basic | 29,164 | 26,386 | |||||
| Diluted | 29,290 | 27,004 | |||||
(1) Acquisition costs include legal, accounting, banking, consulting, diligence, and other costs related to completed and contemplated acquisitions.
(2) Non same-store adjustment includes revenue and costs, and associated gross profit, related to our Services segment wellness centers and host partners with less than six full quarters of operating results, and also include pre-opening expenses.
(3) Integration costs and costs of discontinued clinics represent costs related to integrating the acquired businesses including personnel costs such as severance and signing bonuses, consulting costs, contract termination, and IT conversion costs. Depending on the type of costs, the costs are primarily in the Products segment and the corporate segment. Costs of discontinued clinics represent costs to close Service segment locations.
PetIQ, Inc.Pro forma Impact of Loss of Distribution(Unaudited, in 000’s)
| For the Three Months Ended | For the Year Ended | |||||||||||||
| March 31 | June 30 | September 30 | December 31 | December 31, 2021 | ||||||||||
| Total net sales | $ | 254,347 | 271,011 | 210,534 | 196,636 | $ | 932,528 | |||||||
| Lost Distribution | (20,250 | ) | (11,830 | ) | (3,510 | ) | (480 | ) | (36,070 | ) | ||||
| Pro forma Net Sales | 234,097 | 259,181 | 207,024 | 196,156 | 896,458 | |||||||||
| Total Adjusted EBITDA | 26,861 | 34,359 | 16,364 | 15,308 | 92,892 | |||||||||
| Lost Distribution | (1,012 | ) | (592 | ) | (175 | ) | (24 | ) | (1,803 | ) | ||||
| Pro forma Adjusted EBITDA | $ | 25,849 | 33,767 | 16,189 | 15,284 | $ | 91,089 | |||||||
